Table 1 Summary of cohort data
| Â | Â | Overall | Cognitive status | p | |
|---|---|---|---|---|---|
Impaired | Normal | ||||
Demographics | Â | Â | Â | Â | Â |
| Â | Total (M/F) | 706 (329/377) | 344 (161/183) | 362 (168/194) | 0.9766 |
|  | Average age at death (standard deviation) | 85.15 (10.27) | 87.45 (8.91) | 82.96 (10.98) |  < 0.0001* |
Neuropathologic data | Â | Â | Â | Â | |
| Â | Presence of hippocampal ARTAG (%) | 166 (26.90%) | 96 (31.27%) | 70 (22.58%) | 0.0191 |
| Â | Braak NFT Stage | Â | Â | Â | 0.4282 |
| Â | Â 0 | 64 (9.07%) | 33 (9.59%) | 31 (8.56%) | Â |
| Â | Â I | 111 (15.72%) | 46 (13.37%) | 65 (17.96%) | Â |
| Â | Â II | 189 (26.77%) | 89 (25.87%) | 100 (27.62%) | Â |
| Â | Â III | 186 (26.35%) | 93 (27.03%) | 93 (25.69%) | Â |
| Â | Â IV | 126 (17.85%) | 69 (20.06%) | 57 (15.75%) | Â |
| Â | Â V | 29 (4.11%) | 13 (3.78%) | 16 (4.42%) | Â |
| Â | CERAD Score | Â | Â | Â | 0.4829 |
| Â | Â C0 | 565 (80.03%) | 265 (77.03%) | 300 (82.87%) | Â |
| Â | Â C1 | 111 (15.72%) | 59 (17.15%) | 52 (14.36%) | Â |
Genetics Data | Â | Â | Â | Â | |
| Â | Presence of E2 APOE allele | 22 (22.45%) | 12 (30.77%) | 10 (16.95%) | 0.1746 |
| Â | Presence of E4 APOE allele | 15 (15.31%) | 3 (7.69%) | 12 (20.34%) | 0.1569 |
| Â | APOE Genotype | Â | Â | Â | 0.3225 |
| Â | Â APOE2,2 | 3 (3.06%) | 2 (5.13%) | 1 (1.69%) | Â |
| Â | Â APOE2,3 | 17 (17.35%) | 9 (23.08%) | 8 (13.56%) | Â |
| Â | Â APOE2,4 | 2 (2.04%) | 1 (2.56%) | 1 (1.69%) | Â |
| Â | Â APOE3,3 | 63 (64.29%) | 25 (64.10%) | 38 (64.41%) | Â |
| Â | Â APOE3,4 | 10 (10.20%) | 2 (5.13%) | 8 (13.56%) | Â |
| Â | Â APOE4,4 | 3 (3.06%) | 0 (0%) | 3 (5.08%) | Â |